FINWIRES · TerminalLIVE
FINWIRES

Kontoor Brands' Helly Hansen Seen Driving Growth Transition, UBS Says

By

Kontoor Brands' (KTB) two core brands have significant long-term potential across categories, channels and geographies, and the company could transition from a cash flow stock to a growth stock after the planned sale of its Lee business, UBS Securities said.

The investment firm said in a note Monday it remains bullish on Helly Hansen's outlook following a US-focused analysis and believes the brand could lift Kontoor's long-term sales growth to the mid-single-digit percentage range from low-single-digit.

UBS pointed to a runway for Helly Hansen to expand gradually across key wholesale accounts including Dick's Sporting Goods, REI, and Scheels following an initial test at House of Sport, alongside accelerating direct-to-consumer growth from higher marketing investment and an improved product pipeline.

The brokerage forecasts Helly Hansen's revenue will reach more than $1 billion by fiscal 2030, driven in part by its US business more than doubling to about $330 million from roughly $150 million in fiscal 2025.

UBS maintained its buy rating, with a price target of $131.

Price: $83.90, Change: $+1.91, Percent Change: +2.33%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC